Navigation Links
Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305
Date:8/6/2009

ce unplanned cash requirements, and may not received additional anticipated payments under its collaborations, any of which could shorten the estimated period in which Curis will have cash to fund its operations and which could also adversely affect Curis' estimated operating expenses for 2009 and beyond. - Curis faces risks relating to its ability to enter into and maintain planned collaborations for development candidates under its targeted cancer programs, its ability to maintain its current collaborations with Genentech and Debiopharm, and the risk that any such collaborators will not perform adequately. - Curis also faces other risk factors identified in its Annual Report on Form 10-K for the year ended December 31, 2008, its Quarterly Report for the Quarter ended June 30, 2009 and other filings that it periodically makes with the Securities and Exchange Commission.

In addition, any forward-looking statements represent the views only as of today and should not be relied upon as representing Curis' views as of any subsequent date. Curis disclaims any intention or obligation to update any of the forward-looking statements after the date of this press release whether as a result of new information, future events or otherwise.

    Debiopharm S.A. Contacts
    Dr Jean-Maurice Dumont
    Director, Search & Evaluation
    Department
    jmdumont@debiopharm.com

    Maurice Wagner
    Director Corporate Affairs &
    Communication mwagner@debiopharm.com
    Tel.: +41(0)21-321-01-11
    Fax: +41(0)21-321-01-69

    Additional Media Contacts

    In London

    Maitland
    Brian Hudspith
    Tel: +44(0)20-7379-5151
    bhudspith@maitland.co.uk

    In New York

    Russo Partners, LLC
    
'/>"/>
SOURCE Debiopharm Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic
2. Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours
3. Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions
4. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
5. Japanese Cancer Association and Debiopharm Honour Japanese Research
6. Debiopharm Signs License Agreement for Marketing of Salvacyl(R)/Moapar(R) 3-Month in Treatment of Sexual Deviations
7. Debiopharm and EPFL Establish an Oncology Chair
8. Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award
9. Debiopharm Receives cGMP Certification for Quality Control of its Drug Products
10. The Debiopharm Life Sciences Award Goes to Dr Nusser for his Outstanding Research in Neuroscience
11. Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... TIKVAH, Israel , Dec. 15, 2014 ... ), a leading developer of adult stem cell technologies ... Cell Therapeutics Ltd. was awarded a grant of approximately ... of the Chief Scientist (OCS).  This is the eighth ... support from the Office of the Chief Scientist, which ...
(Date:12/15/2014)... 2014  Origin Agritech Limited (NASDAQ GS: SEED) (" Origin ... crop seeds in China , today announced ... 2014 ended September 30, 2014, before the market opens on ... a teleconference on January 8, 2015, at 8:00 a.m. ET ... discuss the results. To participate in the call, please dial ...
(Date:12/13/2014)... Dec. 12, 2014 /CNW/ - MaRS and Virgin Unite Canada, ... they have joined forces to support Canadian entrepreneurs tackling social ... Group Founder was at the MaRS Centre to announce the ... impact venture fund. This fund has $1 million in seed ... Vancouver -based Mindset Social Innovation Foundation, founded by ...
(Date:12/13/2014)... 12, 2014 Trend lines for photonics ... global economic growth, Eugene Arthurs, CEO of SPIE, ... in a featured talk at OPTIC (Optics and Photonics ... National Chung Hsing University in Taichung. , As examples, ... future energy supplies and soon to hit US$50 billion ...
Breaking Biology Technology:BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 2Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 3MaRS and Virgin Unite partner to invest in business as a force for good 2MaRS and Virgin Unite partner to invest in business as a force for good 3Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 2Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 3Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 4Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 5
... Anticipating a catastrophic increase in Alzheimer,s disease and related ... Plan for Alzheimer,s disease, a disease estimated to double ... a 10-year course of action with guiding principles, goals ... crisis.   Alzheimer,s will soon soar to ...
... 2011 GlobalCare Clinical Trials, Ltd, (GlobalCare) today ... selected clinical study visits at convenient locations – ... – for study patients to support phase I-IV ... and personalized medicine in all age groups. GlobalCare,s ...
... Inc. (NYSE Amex: PTN ) announced that it ... Stock Conference on Tuesday, March 15, 2011, at 12:00 p.m. ... Carlton Laguna Niguel in Dana Point, CA. ... Technologies, will provide an update on Palatin,s corporate and development ...
Cached Biology Technology:California Leaders Confront Alarming Rise in Alzheimer's Cases 2California Leaders Confront Alarming Rise in Alzheimer's Cases 3GlobalCare Clinical Trials, Ltd Announces Company Expansion Into Latin America 2GlobalCare Clinical Trials, Ltd Announces Company Expansion Into Latin America 3GlobalCare Clinical Trials, Ltd Announces Company Expansion Into Latin America 4
(Date:11/21/2014)... November 18, 2014 According to ... by Systems (Video, RFID, Access Control, Intrusion Detection, Parking ... Banks, Government), Component Service Geography - Global Forecasts to ... is projected to be around $25 Billion in 2014 ... growing at a CAGR of 8.69%. Browse ...
(Date:11/18/2014)... Nov. 18, 2014  The Secure Identity & ... today jointly announce the formation of The Airport ... its Identity and Biometric Entry and Exit ... received official support from BORDERPOL, the international non-profit ... and provide expertise regarding border security, traveler and ...
(Date:11/12/2014)... Nov. 12, 2014 Crossmatch™, a leading provider ... U.are.U ® fingerprint readers have been deployed throughout ... Central Mexico . The bakery chain implemented ... payroll issues caused by employees clocking in for each ... fingerprint readers, Montparnasse relied on paper timecards and a ...
Breaking Biology News(10 mins):Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... Researchers at the University of Michigan Comprehensive Cancer Center ... treat multiple types of cancer. A study, published this ... that AT-406 effectively targets proteins that block normal cell death ... while not harming normal cells. The researchers believe the drug ...
... 29, 2011)Uterine fibroid embolizationan interventional radiology treatment for ... in the muscular wall of the uterusimproves a ... are specifically caused by those fibroids, confirm researchers ... Scientific Meeting in Chicago, Ill. "Uterine fibroid ...
... formulation of antioxidants taken orally before imaging with ionizing ... of Interventional Radiology,s 36th Annual Scientific Meeting in Chicago, ... clinical trial of its kind, as much as a ... administering the formula prior to CT scans. "In ...
Cached Biology News:New cancer drug discovered at U-M heads to clinical trials 2Fibroids cause women's lower urinary tract problems: uterine fibroid embolization helps 2Fibroids cause women's lower urinary tract problems: uterine fibroid embolization helps 3Antioxidant formula prior to radiation exposure may prevent DNA injury 2